Salicylic acid, acetate
RTECS #
VO0700000
CAS #
Updated
March 2019
Molecular Weight
180.17
Molecular Formula
C9H8O4
Synonyms
2-(Acetyloxy)benzoic acid
2-Acetoxybenzoic acid
A.S.A.
A.S.A. empirin
AC 5230
Acenterine
Acesal
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetylin
Acetylsal
Acetylsalicylic acid
Acetylsalicylic acid (ACGIH)
Acetylsalicylsaure (German)
Acide acetylsalicylique (French)
Acido acetilsalicilico (Italian)
Acido O-acetil-benzoico (Italian)
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
ASA
Asagran
Aspergum
Aspirdrops
Aspirin
Aspirina 03
Aspro Clear
Asteric
Benaspir
Benzoic acid, 2-(acetyloxy)- (9CI)
Bialpirinia
Caprin
Colfarit
Contrheuma retard
Delgesic
Dolean pH 8
Duramax
ECM
Ecotrin
Empirin
Endydol
Entericin
Enterosarine
Entrophen
Globoid
Helicon
Idragin
Istopirin
Kapsazal
Kyselina 2-acetoxybenzoova (Czech)
Kyselina acetylsalicylova (Czech)
Measurin
Medisyl
Micristin
Neuronika
Novid
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
Polopiryna
Rheumin tabletten
Rhonal
Salacetin
Salcetogen
Saletin
Solpyron
Triple-sal
Xaxa
Yasta
Zorprin
2-Acetoxybenzoic acid
A.S.A.
A.S.A. empirin
AC 5230
Acenterine
Acesal
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetylin
Acetylsal
Acetylsalicylic acid
Acetylsalicylic acid (ACGIH)
Acetylsalicylsaure (German)
Acide acetylsalicylique (French)
Acido acetilsalicilico (Italian)
Acido O-acetil-benzoico (Italian)
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
ASA
Asagran
Aspergum
Aspirdrops
Aspirin
Aspirina 03
Aspro Clear
Asteric
Benaspir
Benzoic acid, 2-(acetyloxy)- (9CI)
Bialpirinia
Caprin
Colfarit
Contrheuma retard
Delgesic
Dolean pH 8
Duramax
ECM
Ecotrin
Empirin
Endydol
Entericin
Enterosarine
Entrophen
Globoid
Helicon
Idragin
Istopirin
Kapsazal
Kyselina 2-acetoxybenzoova (Czech)
Kyselina acetylsalicylova (Czech)
Measurin
Medisyl
Micristin
Neuronika
Novid
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
Polopiryna
Rheumin tabletten
Rhonal
Salacetin
Salcetogen
Saletin
Solpyron
Triple-sal
Xaxa
Yasta
Zorprin
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| skin /human | 10% | CODEDG 60,325,2009 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | fibroblast/human | 100 mg/L | ACYTAN 16,41,1972 |
| Cytogenetic Analysis | leukocyte/human | 100 µg/L | SCIEAS 171,829,1971 |
| Cytogenetic Analysis | lymphocyte/human | 10 mg/L | BEXBAN 78,1194,1974 |
| Cytogenetic Analysis | lung/hamster | 1660 mg/L | GMCRDC 27,95,1981 |
| DNA inhibition | lymphocyte/human | 100 µmol/L | FEPRA7 36,1748,1977 |
| DNA repair | /Bacillus subtilis | 5 mg/disc | JNUDAT 34,183,1992 |
| micronucleus test | lung/hamster | 626 µmol/L/48H (-enzymatic activation step) | MUTAEX 26,709,2011 |
| morphological transform | embryo/rat | 108 µg/plate | JJATDK 1,190,1981 |
| other mutation test systems | lymphocyte/human | 75 mg/L | NEZAAQ 37,673,1982 |
| sister chromatid exchange | intraperitoneal/mouse | 100 mg/kg | MUREAV 370,1,1996 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| intrauterine/rat | 2 mg/kg (4D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | CCPTAY 24,283,1981 |
| oral/mouse | 1200 mg/kg (8-9D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | LANCAO 1,606,1965 |
| oral/mouse | 800 mg/kg (17D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Other effects to embryo or fetus Reproductive: Other developmental abnormalities | APTOA6 29,250,1971 |
| oral/mouse | 19200 mg/kg (6-21D pregnant) | Reproductive: Effects on newborn: Stillbirth Reproductive: Effects on newborn: Other neonatal measures or effects | LANCAO 1,565,1964 |
| oral/mouse | 2500 mg/kg (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | TXCYAC 37,315,1985 |
| oral/cat | 300 mg/kg (10-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | TJADAB 14,21,1976 |
| oral/rabbit | 800 mg/kg (8-15D pregnant) | Reproductive: Specific developmental abnormalities: Body wall Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Specific developmental abnormalities: Musculoskeletal system | BANMAC 159,433,1975 |
| oral/rabbit | 1800 mg/kg (8-16D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Effects on embryo or fetus: Fetal death | TXAPA9 10,244,1967 |
| oral/rabbit | 1750 mg/kg (6-12D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | LANCAO 1,763,1964 |
| oral/rabbit | 600 mg/kg (2D prior to copulation) | Reproductive: Effects on fertility: Other measures of fertility | JJPAAZ 28,909,1978 |
| oral/Dog | 3200 mg/kg (23-30D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Specific developmental abnormalities: Respiratory system | TJADAB 20,313,1979 |
| oral/woman | 7500 mg/kg (34-37W pregnant) | Reproductive: Other effects on female Reproductive: Effects on newborn: Stillbirth | AJPEEK 15,39,1998 |
| oral/woman | 700 mg/kg (35-36W pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Effects on newborn: Biochemical and metabolic | CPEDAM 34,174,1995 |
| oral/woman | 546 mg/kg (37-39W pregnant) | Reproductive: Effects on newborn: Other postnatal measures or effects | CPEDAM 32,740,1993 |
| oral/woman | 546 mg/kg (37-39W pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Other developmental abnormalities | CPEDAM 32,740,1993 |
| oral/woman | 17550 mg/kg (12-39W pregnant) | Reproductive: Maternal effects: Parturition | LANCAO 2,1159,1973 |
| oral/woman | 100 mg/kg (37W pregnant) | Reproductive: Effects on newborn: Other neonatal measures or effects | NEJMAG 307,909,1982 |
| oral/woman | 17280 mg/kg (1-39W pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Specific developmental abnormalities: Respiratory system Reproductive: Effects on newborn: Apgar score (human only) | JOPDAB 92,478,1978 |
| oral/woman | 189 mg/kg (12-39W pregnant) | Reproductive: Maternal effects: Parturition Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Blood and lymphatic systems (including spleen and marrow) | NEJMAG 321,357,1989 |
| oral/rat | 1 gm/kg (12D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death | TJADAB 27,261,1983 |
| oral/rat | 2100 mg/kg (14D male) | Reproductive: Paternal effects: Testes, epididymis, sperm duct | IJEBA6 18,1408,1980 |
| oral/rat | 200 mg/kg (9D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TJADAB 16,127,1977 |
| oral/rat | 10 mg/kg (22D pregnant) | Reproductive: Maternal effects: Parturition Reproductive: Effects on newborn: Stillbirth Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) | NATUAS 240,21,1972 |
| oral/rat | 500 mg/kg (9D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Eye, ear Reproductive: Specific developmental abnormalities: Musculoskeletal system | ANREAK 163,175,1969 |
| oral/rat | 125 mg/kg (12D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | TJADAB 27,261,1983 |
| oral/rat | 1 gm/kg (3D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | YHHPAL 31,416,1996 |
| oral/mouse | 3825 mg/kg (1D preg-30D after birth) | Reproductive: Effects on newborn: Other postnatal measures or effects | BJCAAI 88,1480,2003 |
| oral/rat | 250 mg/kg (9D pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Specific developmental abnormalities: Respiratory system Reproductive: Other developmental abnormalities | TOXID9 60,220,2001 |
| oral/rat | 500 mg/kg (10D pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Specific developmental abnormalities: Respiratory system Reproductive: Other developmental abnormalities | TOXID9 60,220,2001 |
| oral/rat | 500 mg/kg (11D pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system | TOXID9 60,220,2001 |
| oral/rat | 3000 mg/kg (6-17D pregnant) | Reproductive: Specific developmental abnormalities: Respiratory system Reproductive: Other developmental abnormalities | TOXID9 60,220,2001 |
| oral/rat | 720 mg/kg (18-21D pregnant) | Reproductive: Effects on newborn: Other postnatal measures or effects | TXCYAC 232,257,2007 |
| oral/rabbit | 4550 mg/kg (7-19D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | BDERB* 68,38,2003 |
| oral/rat | 250 mg/kg (9D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death | BDERB* 68,27,2003 |
| oral/rat | 500 mg/kg (9D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | BDERB* 68,27,2003 |
| oral/rat | 500 mg/kg (9D pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system Reproductive: Other developmental abnormalities | BDERB* 68,27,2003 |
| oral/rat | 625 mg/kg (9D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | BDERB* 68,27,2003 |
| oral/rat | 625 mg/kg (10D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | BDERB* 68,27,2003 |
| oral/rat | 625 mg/kg (10D pregnant) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system | BDERB* 68,27,2003 |
| oral/rat | 500 mg/kg (10D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | BDERB* 68,27,2003 |
| oral/rat | 750 mg/kg (10D pregnant) | Reproductive: Other developmental abnormalities | BDERB* 68,27,2003 |
| oral/rat | 500 mg/kg (11D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | BDERB* 68,27,2003 |
| oral/rat | 750 mg/kg (11D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Musculoskeletal system | BDERB* 68,27,2003 |
| oral/rat | 750 mg/kg (11D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | BDERB* 68,27,2003 |
| oral/rat | 600 mg/kg (6-17D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death | BDERB* 68,27,2003 |
| oral/rat | 3000 mg/kg (6-17D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | BDERB* 68,27,2003 |
| oral/rat | 3000 mg/kg (6-17D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system | BDERB* 68,27,2003 |
| oral/rat | 3000 mg/kg (6-17D pregnant) | Reproductive: Specific developmental abnormalities: Gastrointestinal system Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Other developmental abnormalities | BDERB* 68,27,2003 |
| oral/rat | 2700 mg/kg (7-16D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Other developmental abnormalities | TOLED5 196S,S183,2010 |
| oral/rat | 2800 mg/kg (7-16D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Other effects to embryo or fetus | TOLED5 196S,S183,2010 |
| oral/rat | 250 mg/kg (10D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Musculoskeletal system | RTOPDW 54,308,2009 |
| oral/rat | 500 mg/kg (10D pregnant) | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | RTOPDW 54,308,2009 |
| subcutaneous/rat | 1800 mg/kg (12D male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | INJFA3 23,282,1978 |
| subcutaneous/rat | 380 mg/kg (9D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Other developmental abnormalities | BCPCA6 22,407,1973 |
| subcutaneous/rat | 500 mg/kg (11D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | RCOCB8 38,209,1982 |
| subcutaneous/rat | 500 mg/kg (11D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | RCOCB8 38,209,1982 |
| subcutaneous/rat | 500 mg/kg (11D pregnant) | Reproductive: Effects on embryo or fetus: Extra embryonic structures (e.g., placenta, umbilical cord) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) | RCOCB8 39,179,1983 |
| subcutaneous/rat | 300 mg/kg (1D prior to copulation) | Reproductive: Effects on fertility: Other measures of fertility | PRGLBA 1,3,1972 |
| subcutaneous/mouse | 500 mg/kg (11D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | JTSCDR 7,177,1982 |
| unreported route/rabbit | 11250 mg/kg (16-30D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death | AKGIAO 43(12),10,1967 |
| unreported route/Dog | 3 gm/kg (20-34D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death | JZKEDZ 6,37,1980 |
| unreported route/rat | 3500 mg/kg (6-15D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system Reproductive: Other developmental abnormalities | JACTDZ 2(4),325,1983 |
| unreported route/woman | 1200 mg/kg (20D prior to copulation) | Reproductive: Maternal effects: Menstrual cycle changes or disorders | CCPTAY 29,181,1984 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/Chicken, neurons | Inhibitor Concentration (50 percent kill): 8586 µmol/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (10 percent kill): 2630 µmol/L/21H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (50 percent kill): 5720 µmol/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 7,653,1993 |
| In Vitro/Chicken, neurons | Inhibitor Concentration (10 percent kill): 2460 µmol/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 7,653,1993 |
| In Vitro/Hamster, lung fibroblast | Inhibitor Concentration (50 percent kill): 1.4 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Hamster, lung fibroblast | Inhibitor Concentration (10 percent kill): 0.36 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Human, blood (whole or unspecified cells) | Inhibitor Concentration Low: 1 mmol/L | Blood: Change in clotting factors | JOETD7 134,460,2011 |
| In Vitro/Human, fibroblast | Inhibitor Concentration Low: 30 mg/L/6H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PYTOEY 34,202,2017 |
| In Vitro/Human, HeLa cell | Inhibitor Concentration (50 percent kill): 2.8 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Human, HeLa cell | Inhibitor Concentration (10 percent kill): 0.79 mmol/L/60H | In Vitro Toxicity Studies: Cell counting | TIVIEQ 7,511,1993 |
| In Vitro/Human, liver | Inhibitor Concentration (50 percent kill): 4.97 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Human, liver | Inhibitor Concentration (10 percent kill): 1.8 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Human, liver | Inhibitor Concentration (50 percent kill): >200 µmol/L/48H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 30,429,2015 |
| In Vitro/Human, liver | Inhibitor Concentration (50 percent kill): 1024.7 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,760,2013 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 303.4 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,760,2013 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 3420 mg/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 622 µmol/L | In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TIVIEQ 34,161,2016 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 864 µmol/L/1H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 34,161,2016 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 622 µmol/L/1H | Biochemical: Metabolism (intermediary): Glycolytic | TIVIEQ 34,161,2016 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 693.4 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | PYTOEY 21,1473,2014 |
| In Vitro/Human, lung tumor | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | PYTOEY 21,1473,2014 |
| In Vitro/Human, lung tumor | Inhibitor Concentration (50 percent kill): 2.4 mmol/L/96H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TXCYAC 278,374,2010 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration (50 percent kill): 2740 mg/L | In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 596 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Human, skin | Inhibitor Concentration (50 percent kill): 330000 mg/L/1M | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 6,367,1992 |
| In Vitro/jkh | Inhibitor Concentration (50 percent kill): 2 mmol/L/96H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TXCYAC 278,374,2010 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 7.3 mmol/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 3.6 mmol/L/72H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 17.9 mmol/L/48H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 4.2 mmol/L/72H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 9.6 mmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 3.1 mmol/L/72H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,449,1991 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 538 mg/L/48H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): 15 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (10 percent kill): 4.4 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration (50 percent kill): >100 µmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 30,429,2015 |
| In Vitro/Mouse, liver | Inhibitor Concentration (50 percent kill): >6.7 mmol/L/2H | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | TIVIEQ 4,783,1990 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration Low: 1 µmol/L/24H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 152,151,2014 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration (50 percent kill): 71.7 µmol/L/48H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 154,453,2014 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration (50 percent kill): >100 µmol/L/20H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 154,453,2014 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration (50 percent kill): >100 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | JOETD7 154,453,2014 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration (50 percent kill): 16.4 mg/L/48H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 150,223,2013 |
| In Vitro/paa | Inhibitor Concentration Low: 291 µmol/L/44H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1416,2013 |
| In Vitro/qpa | Inhibitor Concentration Low: 250 µmol/L/5M | In Vitro Toxicity Studies: Other assays | FTRPAE 90,209,2013 |
| In Vitro/Rat, intestinal | Inhibitor Concentration (50 percent kill): >10 mmol/L/5H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 28,1296,2014 |
| In Vitro/Rat, intestinal | Inhibitor Concentration Low: 10 mmol/L/5H | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,1296,2014 |
| In Vitro/Rat, liver | Inhibitor Concentration Low: 2 mmol/L/20H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 8,55,1994 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1160 mg/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,1347,2013 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 2.3 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Rat, liver | Inhibitor Concentration (10 percent kill): 0.83 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 6,47,1992 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1215 mg/L/20H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1283 mg/L/20H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 1355 mg/L/20H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver | Inhibitor Concentration (50 percent kill): 817 mg/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): >1500 mg/L/20H | In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): >1500 mg/L/20H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): >1500 mg/L/20H | In Vitro Toxicity Studies: Cell protein synthesis | TIVIEQ 5,543,1991 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): >1500 mg/L/20H | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | TIVIEQ 5,543,1991 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 1.74 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (50 percent kill): 10 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (10 percent kill): 0.11 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (75 percent kill): 9.77 gm/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (10 percent kill): 1 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| In Vitro/Rat, lung | Inhibitor Concentration (75 percent kill): 42.7 gm/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 7,111,1993 |
| intraperitoneal/mouse | lowest published toxic dose: 100 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FTRPAE 82,1190,2011 |
| intraperitoneal/mouse | lowest published toxic dose: 10 mg/kg | Behavioral: Analgesia | JOETD7 150,595,2013 |
| intraperitoneal/mouse | lowest published toxic dose: 45 mg/kg | Behavioral: Analgesia Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 144,712,2012 |
| intraperitoneal/mouse | lowest published toxic dose: 10 mg/kg | Blood: Change in clotting factors | JOETD7 155,1236,2014 |
| intraperitoneal/mouse | lowest published lethal dose: 1216 mg/kg | PCJOAU 34,353,2000 | |
| intraperitoneal/mouse | lowest published toxic dose: 100 mg/kg | Gastrointestinal: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes Biochemical: Metabolism (intermediary): Histamines (including liberation not immunochemical in origin) | EJPHAZ 460,63,2003 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 167 mg/kg | USXXAM #6656449 | |
| intraperitoneal/mouse | lowest published toxic dose: 10 mg/kg | Behavioral: Change in psychophysiological tests | PSCHDL 171,382,2004 |
| intraperitoneal/rat | lowest published toxic dose: 20 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | INJPD2 41,75,2009 |
| intraperitoneal/rat | lowest published toxic dose: 4.026 mg/kg | Nutritional and Gross Metabolic: Body temperature decrease | JPETAB 327,665,2008 |
| intraperitoneal/rat | lowest published toxic dose: 500 mg/kg | Liver: Other changes Biochemical: Metabolism (intermediary): Lipids including transport | EKFAE9 59,43,1996 |
| intraperitoneal/rat | lowest published toxic dose: 50 mg/kg | Behavioral: Analgesia | BJPCBM 129,343,2000 |
| intraperitoneal/rat | lethal dose (50 percent kill): 340 mg/kg | NYKZAU 62,11,1966 | |
| intraperitoneal/rat | lowest published toxic dose: 100 mg/kg | Behavioral: Analgesia Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FCTOD7 48,61,2010 |
| intravenous/Dog | lethal dose (50 percent kill): 681 mg/kg | Behavioral: Analgesia | AIPTAK 149,571,1964 |
| intravenous/guinea pig | lowest published toxic dose: 2 mg/kg | Blood: Change in clotting factors | EJPHAZ 498,179,2004 |
| intravenous/human | lowest published toxic dose: 14.3 mg/kg | Behavioral: Analgesia | EJNSC* 26,1344,2007 |
| intravenous/monkey | lowest published toxic dose: 1 mg/kg | Blood: Change in clotting factors | PHMCAA 70,100,2004 |
| intravenous/mouse | lowest published toxic dose: 250 mg/kg | Vascular: Measurement of regional blood flow Gastrointestinal: Other changes Blood: Other changes | BJPCBM 143,193,2004 |
| intravenous/mouse | lowest published toxic dose: 30 mg/kg | Blood: Hemorrhage | TOXIA6 51,1131,2008 |
| intravenous/mouse | lowest published toxic dose: 10 mg/kg | Vascular: Measurement of regional blood flow | EJPHAZ 455,53,2002 |
| intravenous/mouse | lowest published toxic dose: 14.1 mg/kg | Behavioral: Analgesia | NRSCDN 132,49,2005 |
| intravenous/rat | lowest published toxic dose: 30 mg/kg | Blood: Change in clotting factors | TOXIA6 51,1131,2008 |
| intravenous/rat | lethal dose (50 percent kill): 495 mg/kg | GWXXAW #4101325 | |
| oral/child | lowest published toxic dose: 780 mg/kg | Cardiac: Cardiomyopathy including infarction Lung, Thorax, or Respiration: Acute pulmonary edema Kidney, Ureter, and Bladder: Hematuria | JEMME* 13,657,1995 |
| oral/child | lowest published toxic dose: 10 mg/kg/1D- intermittent | Lung, Thorax, or Respiration: Acute pulmonary edema Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, and Bladder: Urine volume decreased or anuria | CTOXAO 18,247,1981 |
| oral/child | lowest published lethal dose: 104 mg/kg | Lung, Thorax, or Respiration: Acute pulmonary edema Gastrointestinal: Nausea or vomiting Blood: Hemorrhage | LANCAO 2,809,1952 |
| oral/child | lowest published toxic dose: 39 mg/kg/13D- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse | AJDCAI 139,453,1985 |
| oral/Dog | lethal dose (50 percent kill): 700 mg/kg | Behavioral: Altered sleep time (including change in righting reflex) Lung, Thorax, or Respiration: Respiratory depression | ARZNAD 21,719,1971 |
| oral/guinea pig | lethal dose (50 percent kill): 1075 mg/kg | Behavioral: Altered sleep time (including change in righting reflex) Behavioral: Somnolence (general depressed activity) Behavioral: Tremor | JAPMA8 47,479,1958 |
| oral/hamster | lethal dose (50 percent kill): 3500 mg/kg | ATSUDG 7,365,1984 | |
| oral/human | lowest published toxic dose: 5.4 mg/kg | Vascular: Other changes Blood: Other changes | CLPTAT 67,299,2000 |
| oral/human | lowest published toxic dose: 669 mg/kg/11D | Liver: Liver function tests impaired | AJHPA9 35,330,1978 |
| oral/human | lowest published toxic dose: 2880 mg/kg/8W | Ear: Tinnitus Gastrointestinal: Nausea or vomiting Gastrointestinal: Decreased motility or constipation | ARZNAD 33,631,1983 |
| oral/human | lowest published toxic dose: 480 mg/kg/7D- intermittent | Ear: Tinnitus Behavioral: Somnolence (general depressed activity) Gastrointestinal: Other changes | ARZNAD 25,281,1975 |
| oral/human | lowest published toxic dose: 1050 mg/kg/14D- intermittent | Vascular: Other changes | CLPTAT 67,530,2000 |
| oral/human | lowest published toxic dose: 2.7 mg/kg | Kidney, Ureter, and Bladder: Other changes in urine composition Immunological Including Allergic: Other immediate (humoral): uticaria, allergic rhinitis, serum sickness (multiple organ involvement) Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JACIBY 113,771,2004 |
| oral/human | lowest published toxic dose: 1.2 mg/kg | Blood: Change in clotting factors Blood: Other changes | EJPHAZ 499,315,2004 |
| oral/human | lowest published toxic dose: 2.14 mg/kg | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood: Other changes Biochemical: Metabolism (intermediary): Lipids including transport | FCLPH* 17,363,2003 |
| oral/human | lowest published toxic dose: 7.143 mg/kg | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | BCLPT* 104,17,2008 |
| oral/infant | lowest published toxic dose: 120 mg/kg | Lung, Thorax, or Respiration: Respiratory stimulation Kidney, Ureter, and Bladder: Hematuria Nutritional and Gross Metabolic: Dehydration | BMJOAE 1,1081,1979 |
| oral/mammal (species unspecified) | lethal dose (50 percent kill): 1750 mg/kg | IJMRAQ 81,621,1985 | |
| oral/man | lowest published toxic dose: 13036 mg/kg/5Y- intermittent | Gastrointestinal: Other changes Musculoskeletal: Joints Skin: After systemic exposure: Dermatitis, other | AIMEAS 126,665,1997 |
| oral/man | lowest published toxic dose: 1625 mg/kg | Behavioral: Coma Nutritional and Gross Metabolic: Body temperature increase | CPEDAM 24,678,1985 |
| oral/man | lowest published toxic dose: 857 mg/kg | Behavioral: Coma Lung, Thorax, or Respiration: Respiratory stimulation | HUTODJ 7,161,1988 |
| oral/mouse | lethal dose (50 percent kill): 250 mg/kg | USXXAM #6656449 | |
| oral/mouse | lowest published toxic dose: 300 mg/kg | Gastrointestinal: Ulceration or bleeding from stomach | PCJOAU 36,11,2002 |
| oral/mouse | lowest published toxic dose: 23 mg/kg | Behavioral: Analgesia | JPETAB 303,340,2002 |
| oral/mouse | lowest published toxic dose: 200 mg/kg | Gastrointestinal: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other enzymes Biochemical: Metabolism (intermediary): Histamines (including liberation not immunochemical in origin) | EJPHAZ 460,63,2003 |
| oral/mouse | lowest published toxic dose: 100 mg/kg | Behavioral: Change in psychophysiological tests | JPETAB 307,699,2003 |
| oral/mouse | lowest published lethal dose: 1216 mg/kg | FRMCE8 60,203,2005 | |
| oral/mouse | lowest published toxic dose: 50 mg/kg | Blood: Change in clotting factors | FCTOD7 49,3018,2011 |
| oral/mouse | lowest published toxic dose: 10 mg/kg | Behavioral: Analgesia Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 152,540,2014 |
| oral/mouse | lowest published toxic dose: 10 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 149,191,2013 |
| oral/rabbit | lowest published toxic dose: 500 mg/kg | Gastrointestinal: Ulceration or bleeding from stomach Gastrointestinal: Hypermotility, diarrhea Nutritional and Gross Metabolic: Weight loss or decreased weight gain | BDERB* 68,38,2003 |
| oral/rabbit | lethal dose (50 percent kill): 1010 mg/kg | Behavioral: Change in motor activity (specific assay) | GTPZAB 24(3),43,1980 |
| oral/rat | lowest published toxic dose: 150 mg/kg | Behavioral: Abuse | INJPD2 33,350,2001 |
| oral/rat | lowest published toxic dose: 250 mg/kg | Gastrointestinal: Alteration in gastric secretion Gastrointestinal: Ulceration or bleeding from stomach | FCLPH* 16,311,2002 |
| oral/rat | lowest published toxic dose: 17 mg/kg | Behavioral: Analgesia | FATOAO 51,78,1988 |
| oral/rat | lowest published toxic dose: 50 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PHREP* 57,802,2005 |
| oral/rat | lowest published toxic dose: 100 mg/kg | Behavioral: Analgesia Gastrointestinal: Ulceration or bleeding from stomach Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PHREP* 57,802,2005 |
| oral/rat | lowest published toxic dose: 200 mg/kg | Gastrointestinal: Ulceration or bleeding from stomach Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | INJPD2 38,397,2006 |
| oral/rat | lowest published toxic dose: 300 mg/kg | Nutritional and Gross Metabolic: Body temperature decrease | INJPD2 38,408,2006 |
| oral/rat | lowest published toxic dose: 50 mg/kg | Spinal Cord: Other degenerative changes | PHMCAA 69,123,2003 |
| oral/rat | lowest published toxic dose: 50 mg/kg | Gastrointestinal: Alteration in gastric secretion Gastrointestinal: Other changes Biochemical: Metabolism (intermediary): Other | BPBLEO 31,1371,2008 |
| oral/rat | lowest published toxic dose: 120 mg/kg | Gastrointestinal: Necrotic changes Blood: Hemorrhage Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JMCMAR 46,747,2003 |
| oral/rat | lethal dose (50 percent kill): 950 mg/kg | CJPPA3 44,909,1966 | |
| oral/rat | lowest published toxic dose: 100 mg/kg | Behavioral: Analgesia Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 158,271,2014 |
| oral/rat | lowest published toxic dose: 150 mg/kg | Gastrointestinal: Ulceration or bleeding from stomach | FITOT* 82,666,2011 |
| oral/rat | lowest published toxic dose: 500 mg/kg | Gastrointestinal: Ulceration or bleeding from stomach Gastrointestinal: Other changes | PYTOEY 18,91,2011 |
| oral/woman | lowest published toxic dose: 194.4 mg/kg | Ear: Tinnitus Gastrointestinal: Nausea or vomiting | APHRER 38,1186,2004 |
| oral/woman | lowest published toxic dose: 194.4 mg/kg | Ear: Tinnitus Gastrointestinal: Other changes Blood: Other changes | APHRER 38,1186,2004 |
| oral/woman | lowest published toxic dose: 13 mg/kg | Vascular: Other changes Immunological Including Allergic: Other immediate (humoral): uticaria, allergic rhinitis, serum sickness (multiple organ involvement) | APHRER 39,944,2005 |
| oral/woman | lowest published toxic dose: 200 mg/kg | Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, and Bladder: Proteinuria Nutritional and Gross Metabolic: Changes in: Metabolic acidosis | AJKDDP 50,463,2007 |
| oral/woman | lowest published toxic dose: 525 mg/kg/5D- intermittent | Liver: Hepatitis (hepatocellular necrosis), diffuse | AIMEAS 80,74,1974 |
| oral/woman | lowest published toxic dose: 480 mg/kg/5D- intermittent | Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Biochemical: Metabolism (intermediary): Other | NEJMAG 296,418,1977 |
| oral/woman | lowest published toxic dose: 800 mg/kg | Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Musculoskeletal: Other changes | AJEMEN 7,409,1989 |
| rectal/rat | lethal dose (50 percent kill): 790 mg/kg | 34ZIAG -,67,1969 | |
| rectal/woman | lowest published toxic dose: 4550 mg/kg | Brain and Coverings: Encephalitis Behavioral: Coma Cardiac: Arrythmias (indlucing changes in conduction) | APHRER 28,467,1994 |
| skin/mouse | lowest published toxic dose: 50 mg/kg | Immunological Including Allergic: Decrease in cellular immune response | FATOAO 47,84,1984 |
| skin/rat | lowest published toxic dose: 50 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FATOAO 47,84,1984 |
| subcutaneous/mouse | lethal dose (50 percent kill): 1020 mg/kg | CPBTAL 28,1237,1980 | |
| subcutaneous/mouse | lowest published toxic dose: 10 mg/kg | Behavioral: Analgesia | FCLPH* 20,365,2006 |
| subcutaneous/rat | lowest published toxic dose: 5 mg/kg | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PYTOEY 10,375,2003 |
| Tank with water/Zebrafish | lowest published toxic concentration: 1000 µmol/L/48H | Reproductive: Specific developmental abnormalities: Gastrointestinal system | TXAPA9 272,272,2013 |
| unreported route/man | lowest published lethal dose: 294 mg/kg | 85DCAI 2,73,1970 | |
| unreported route/mouse | lethal dose (50 percent kill): 1350 mg/kg | USXXAM #5240918 | |
| unreported route/mouse | lowest published toxic dose: 100 mg/kg | Behavioral: Analgesia | JOETD7 144,726,2012 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/rat | lowest published toxic concentration: 25 mg/m3/4H/17W- intermittent | Brain and Coverings: Recordings from specific areas of CNS Blood: Change in clotting factors Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | GTPZAB 24(3),43,1980 |
| intraperitoneal/mouse | lowest published toxic dose: 700 mg/kg/7D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FTRPAE 81,855,2010 |
| intraperitoneal/mouse | lowest published toxic dose: 14.0 mg/kg/7D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 155,1300,2014 |
| intraperitoneal/rat | lowest published toxic dose: 8750 mg/kg/21D- intermittent | Kidney, Ureter, and Bladder: Changes in both tubules and glomeruli | JDGRAX 19,327,1990 |
| intraperitoneal/rat | lowest published toxic dose: 60 mg/kg/3D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach | CPBTAL 55,76,2007 |
| oral/Dog | lowest published toxic dose: 1200 mg/kg/2D- intermittent | Blood: Change in clotting factors | FATOBP 159,19,1986 |
| oral/Dog | lowest published toxic dose: 12000 mg/kg/10D- intermittent | Blood: Change in clotting factors | FATOAO 49,49,1986 |
| oral/human | lowest published toxic dose: 85.8 mg/kg/30D- intermittent | Gastrointestinal: Ulceration or bleeding from duodeum | NEJMAG 343,834,2000 |
| oral/human | lowest published toxic dose: 10 mg/kg/7D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach | EJCPAS -,S85,2002 |
| oral/human | lowest published toxic dose: 261.507 mg/kg/183D- intermittent | Blood: Change in clotting factors | NSAPCC 372(Suppl 1),147,2006 |
| oral/human | lowest published toxic dose: 6.4 mg/kg/3D- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood: Other changes Biochemical: Metabolism (intermediary): Lipids including transport | FCLPH* 17,363,2003 |
| oral/human | lowest published toxic dose: 3.5 mg/kg/5D- intermittent | Gastrointestinal: Hypermotility, diarrhea Gastrointestinal: Nausea or vomiting | PYTOEY 18,437,2011 |
| oral/human | lowest published toxic dose: 29032 mg/kg/20Y- intermittent | Gastrointestinal: Other changes | BJCAAI 95,1277,2006 |
| oral/human | lowest published toxic dose: 834.29 mg/kg/1Y- intermittent | Gastrointestinal: Other changes Tumorigenic: Active as anti-cancer agent | FCLPH* 23(Suppl 1),111,2009 |
| oral/man | lowest published toxic dose: 30.1 mg/kg/7D- intermittent | Behavioral: Change in psychophysiological tests | PSCHDL 205,151,2009 |
| oral/man | lowest published toxic dose: 0.087 gm/kg/3D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach Gastrointestinal: Other changes | JPHPH* 59,67,2008 |
| oral/man | lowest published toxic dose: 8395 mg/kg/5Y- intermittent | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands | JNCIEQ 97,975,2005 |
| oral/man | lowest published toxic dose: 2555 mg/kg/5Y- intermittent | Blood: Eosinophilia | APHRER 38,2172,2004 |
| oral/mouse | lowest published toxic dose: 12600 mg/kg/7D- intermittent | Blood: Normocytic anemia Blood: Changes in bone marrow not included in above Blood: Changes in leukocyte (WBC) count | INJPD2 36,226,2004 |
| oral/mouse | lowest published toxic dose: 22500 mg/kg/25W- intermittent | Blood: Normocytic anemia Blood: Changes in bone marrow not included in above Blood: Changes in leukocyte (WBC) count | INJPD2 36,226,2004 |
| oral/mouse | lowest published toxic dose: 900 mg/kg/3D- intermittent | Behavioral: Analgesia Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | BPBLEO 31,1761,2008 |
| oral/mouse | lowest published toxic dose: 36 mg/kg/3D- continuous | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JCINAO 119,305,2009 |
| oral/mouse | lowest published toxic dose: 1000 mg/kg/5D- intermittent | Behavioral: Analgesia | FTRPAE 81,178,2010 |
| oral/mouse | lowest published toxic dose: 1400 mg/kg/7D- intermittent | JOETD7 150,501,2013 | |
| oral/mouse | lowest published toxic dose: 70 mg/kg/14D- intermittent | JOETD7 154,163,2014 | |
| oral/mouse | lowest published toxic dose: 1000 mg/kg/10D- intermittent | Blood: Change in clotting factors | JOETD7 151,151,2014 |
| oral/mouse | lowest published toxic dose: 0.3 gm/kg/3D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 152,444,2014 |
| oral/mouse | lowest published toxic dose: 371 mg/kg/7D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 187,259,2016 |
| oral/mouse | lowest published toxic dose: 500 mg/kg/5D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PYTOEY 23,1227,2016 |
| oral/rabbit | lowest published toxic dose: 3250 mg/kg/13D- intermittent | Behavioral: Somnolence (general depressed activity) Gastrointestinal: Hypermotility, diarrhea | BDERB* 68,38,2003 |
| oral/rabbit | lowest published toxic dose: 2500 mg/kg/10D- intermittent | Gastrointestinal: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | BDERB* 68,38,2003 |
| oral/rabbit | lowest published toxic dose: 1750 mg/kg/7D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | BDERB* 68,38,2003 |
| oral/rabbit | lowest published toxic dose: 1500 mg/kg/6D- intermittent | Behavioral: Food intake (animal) | BDERB* 68,38,2003 |
| oral/rat | lowest published toxic dose: 875 mg/kg/7D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | BDERB* 68,27,2003 |
| oral/rat | lowest published toxic dose: 400 mg/kg/2D- intermittent | Blood: Hemorrhage | EJPHAZ 587,209,2008 |
| oral/rat | lowest published toxic dose: 7056 mg/kg/42W- continuous | Tumorigenic: Active as anti-cancer agent | CNREA8 66,4542,2006 |
| oral/rat | lowest published toxic dose: 150 mg/kg/5D- intermittent | Vascular: Other changes Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | ACPSI* 25,1633,2004 |
| oral/rat | lowest published toxic dose: 2100 mg/kg/21D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | EJPHAZ 551,131,2006 |
| oral/rat | lowest published toxic dose: 1440 mg/kg/4D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TXCYAC 232,257,2007 |
| oral/rat | lowest published toxic dose: 360 mg/kg/4D- intermittent | Reproductive: Other effects on female | TXCYAC 232,257,2007 |
| oral/rat | lowest published toxic dose: 1400 mg/kg/2W- intermittent | Cardiac: Other changes Kidney, Ureter, and Bladder: Changes primarily in glomeruli Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | HETOEA 22,143,2003 |
| oral/rat | lowest published toxic dose: 1500 mg/kg/2W- intermittent | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | TXCYAC 188,161,2003 |
| oral/rat | lowest published toxic dose: 180 mg/kg/10D- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | EJPHAZ 477,59,2003 |
| oral/rat | lowest published toxic dose: 32.4 mg/kg/3D- intermittent | Blood: Change in clotting factors | EKFAE9 62,38,1999 |
| oral/rat | lowest published toxic dose: 560 mg/kg/4W- continuous | Skin and Appendages: Tumors Tumorigenic: Protects against induction of experimental tumors Tumorigenic: Active as anti-cancer agent | CALEDQ 143,195,1999 |
| oral/rat | lowest published toxic dose: 2500 mg/kg/10D- intermittent | Endocrine: Hypoglycemia Blood: Other changes | FATOBP 159,75,1986 |
| oral/rat | lowest published toxic dose: 5000 mg/kg/10D- intermittent | Endocrine: Other changes Blood: Other changes | FATOBP 159,75,1986 |
| oral/rat | lowest published toxic dose: 9500 mg/kg/3W- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | JPETAB 89,205,1947 |
| oral/rat | lowest published toxic dose: 200 mg/kg/4D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach | TXAPA9 52,454,1980 |
| oral/rat | lowest published toxic dose: 8127 mg/kg/43W- continuous | Kidney, Ureter, and Bladder: Other changes in urine composition | APTOA6 26,105,1968 |
| oral/rat | lowest published toxic dose: 1320 mg/kg/11D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 194,228,2016 |
| oral/rat | lowest published toxic dose: 1600 mg/kg/16D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 152,522,2014 |
| oral/rat | lowest published toxic dose: 75 mg/kg/15D- intermittent | Blood: Change in clotting factors | JOETD7 159,184,2015 |
| oral/rat | lowest published toxic dose: 145.74 mg/kg/14D- intermittent | Gastrointestinal: Alteration in gastric secretion Gastrointestinal: Gastritis Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases | PYTOEY 23,662,2016 |
| oral/rat | lowest published toxic dose: 600 mg/kg/6D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 187,17,2016 |
| oral/rat | lowest published toxic dose: 1400 mg/kg/7D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | JOETD7 151,343,2014 |
| oral/rat | lowest published toxic dose: 70 mg/kg/14D- intermittent | JOETD7 154,163,2014 | |
| oral/rat | lowest published toxic dose: 600 mg/kg/3D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach | JOETD7 134,195,2011 |
| oral/rat | lowest published toxic dose: 51.5 mg/kg/5D- intermittent | Blood: Change in clotting factors | JOETD7 143,648,2012 |
| oral/rat | lowest published toxic dose: 700 mg/kg/4D- intermittent | Blood: Change in clotting factors Blood: Other changes | FCTOD7 47,1797,2009 |
| oral/rat | lowest published toxic dose: 420 mg/kg/6W- continuous | Cardiac: Changes in heart weight Kidney, Ureter, and Bladder: Changes in blood vessels or in circulation of kidney Vascular: Other changes | CEXPB9 36,162,2009 |
| oral/rat | lowest published toxic dose: 400 mg/kg/5D- intermittent | Gastrointestinal: Other changes Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases | FCTOD7 48,2785,2010 |
| oral/rat | lowest published toxic dose: 12000 mg/kg/120D- continuous | Blood: Other changes Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Plasma proteins not involving coagulation | JPETAB 324,850,2008 |
| oral/rat | lowest published toxic dose: 6000 mg/kg/60D- continuous | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other esterases | JPETAB 324,850,2008 |
| oral/rat | lowest published toxic dose: 10 mg/kg/2D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | PYTOEY 10,375,2003 |
| oral/rat | lowest published toxic dose: 1350 mg/kg/3D- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | HETOEA 28,231,2009 |
| oral/rat | lowest published toxic dose: 450 mg/kg/15D- intermittent | Gastrointestinal: Ulceration or bleeding from stomach | JPETAB 311,1264,2004 |
| oral/woman | lowest published toxic dose: 455 mg/kg/7D- intermittent | Behavioral: Somnolence (general depressed activity) Behavioral: Tremor Nutritional and Gross Metabolic: Body temperature increase | JTCTDW 45,526,2007 |
| oral/woman | lowest published toxic dose: 0.36 mg/kg/24W- intermittent | Lung, Thorax, or Respiration: Tumors | BJCAAI 87,49,2002 |
| oral/woman | lowest published toxic dose: 261 mg/kg/5Y- intermittent | Skin and Appendages: Other: Breast Tumorigenic: Active as anti-cancer agent | CNREA8 63,6096,2003 |
| oral/woman | lowest published toxic dose: 300 mg/kg/3D- intermittent | Behavioral: Coma Nutritional and Gross Metabolic: Changes in: Metabolic acidosis Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NRTXDN 28,33,2007 |
| oral/woman | lowest published toxic dose: 13559 mg/kg/20Y- intermittent | Gastrointestinal: Changes in structure or function of exocrine pancreas Gastrointestinal: Tumors | JNCIEQ 96,22,2004 |
| skin/mouse | lowest published toxic dose: 500 mg/kg/10D- intermittent | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FATOAO 47,84,1984 |
| subcutaneous/mouse | lowest published toxic dose: 2520 mg/kg/3W- continuous | Endocrine: Hypoglycemia Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | SCIEAS 293,1673,2001 |
| subcutaneous/rat | lowest published toxic dose: 840 mg/kg/1W- continuous | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Lipids including transport | SCIEAS 293,1673,2001 |
| subcutaneous/rat | lowest published toxic dose: 2520 mg/kg/3W- continuous | Endocrine: Hypoglycemia Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Metabolism (intermediary): Lipids including transport | SCIEAS 293,1673,2001 |
| unreported route/human | lowest published toxic dose: 8.4 mg/kg/6D- intermittent | Blood: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | JPETAB 322,453,2007 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| American Conference of Governmental Industrial Hygienists (ACGIH) | Threshold Limit Value-time-weighted average 5 mg/m3 | DTLVS* TLV/BEI,2013 |
| TOXICOLOGY REVIEW | BCSTB5 2,695,1974 | |
| TOXICOLOGY REVIEW | DICPBB 9,350,1975 | |
| TOXICOLOGY REVIEW | DICPBB 8,690,1974 | |
| TOXICOLOGY REVIEW | PLMJAP 6,160,1975 | |
| TOXICOLOGY REVIEW | JPHAA3 NS16,147,1976 | |
| TOXICOLOGY REVIEW | AUHPAI 3(3),100,1973 | |
| TOXICOLOGY REVIEW | JRPMAP 12,27,1974 | |
| TOXICOLOGY REVIEW | CLCHAU 19,361,1973 | |
| TOXICOLOGY REVIEW | AJMEAZ 38,409,1965 | |
| TOXICOLOGY REVIEW | ATXKA8 28,135,1971 | |
| TOXICOLOGY REVIEW | AIMDAP 141,358,1981 | |
| TOXICOLOGY REVIEW | JJIND8 94,252,2002 | |
| TOXICOLOGY REVIEW | REPTED 17,255,2003 | |
| TOXICOLOGY REVIEW | MUREAV 488,151,2001 | |
| TOXICOLOGY REVIEW | TOLED5 144,383,2003 | |
| TOXICOLOGY REVIEW | EMMUEG 43,143,2004 | |
| TOXICOLOGY REVIEW | TPHSDY 24,245,2003 | |
| TOXICOLOGY REVIEW | TPHSDY 24,154,2003 | |
| TOXICOLOGY REVIEW | TPHSDY 24,323,2003 | |
| TOXICOLOGY REVIEW | TPHSDY 24,331,2003 | |
| TOXICOLOGY REVIEW | TPHSDY 24,335,2003 | |
| TOXICOLOGY REVIEW | APHRER 37,1675,2003 | |
| TOXICOLOGY REVIEW | APHRER 39,51,2005 | |
| TOXICOLOGY REVIEW | APHRER 39,944,2005 | |
| TOXICOLOGY REVIEW | JPETAB 314,1,2005 | |
| TOXICOLOGY REVIEW | AJMEAZ 119,624,2006 | |
| TOXICOLOGY REVIEW | AJMEAZ 119,552,2006 | |
| TOXICOLOGY REVIEW | AINCM* 7,63,2006 | |
| TOXICOLOGY REVIEW | BPCEM* 17,237,2003 | |
| TOXICOLOGY REVIEW | ENTOX* -,36,2005 | |
| TOXICOLOGY REVIEW | EJIME* 17,529,2006 | |
| TOXICOLOGY REVIEW | DIMON* 40,258,1994 | |
| TOXICOLOGY REVIEW | DIMON* 39,678,1993 | |
| TOXICOLOGY REVIEW | JEMME* 32,63,2007 | |
| TOXICOLOGY REVIEW | ENTOX* -,742,2005 | |
| TOXICOLOGY REVIEW | BJPCBM 146,477,2005 | |
| TOXICOLOGY REVIEW | BJPCBM 147,S241,2006 | |
| TOXICOLOGY REVIEW | TOPADD 32(Suppl. 2),71,2004 | |
| TOXICOLOGY REVIEW | FCLPH* 17,393,2003 | |
| TOXICOLOGY REVIEW | AJEMEN 22,404,2004 | |
| TOXICOLOGY REVIEW | PHREP* 59,247,2007 | |
| TOXICOLOGY REVIEW | MJAUAJ 185,501,2006 | |
| TOXICOLOGY REVIEW | HUTOX* -,411,1996 | |
| TOXICOLOGY REVIEW | JPHPH* 59,117,2008 | |
| TOXICOLOGY REVIEW | JPHPH* 59(Suppl 2),89,2008 | |
| TOXICOLOGY REVIEW | JPHPH* 59(Suppl 2),117,2008 | |
| TOXICOLOGY REVIEW | BPRCR* 16,105,2002 | |
| TOXICOLOGY REVIEW | AJMEAZ 121,464,2008 | |
| TOXICOLOGY REVIEW | BLREV* 3,71,1989 | |
| TOXICOLOGY REVIEW | CLLID* 11,563,2007 | |
| TOXICOLOGY REVIEW | COCPH* -,701,2008 | |
| TOXICOLOGY REVIEW | CLLID* 13,277,2009 | |
| TOXICOLOGY REVIEW | CCACL* 22,357,2006 | |
| TOXICOLOGY REVIEW | DERCL* 25,215,2007 | |
| TOXICOLOGY REVIEW | DERCL* 27,289,2009 | |
| TOXICOLOGY REVIEW | MUTAEX 23,271,2008 | |
| TOXICOLOGY REVIEW | NCLNA* 16,107,1998 | |
| TOXICOLOGY REVIEW | MEDIAV 37,263,2009 | |
| TOXICOLOGY REVIEW | NBREV* 5,1,1981 | |
| TOXICOLOGY REVIEW | NBREV* 11,35,1987 | |
| TOXICOLOGY REVIEW | FCLPH* 22(Suppl 1),30,2008 | |
| TOXICOLOGY REVIEW | FCLPH* 23(Suppl 1),15,2009 | |
| TOXICOLOGY REVIEW | FCLPH* 22,335,2008 | |
| TOXICOLOGY REVIEW | FCLPH* 23,105,2009 | |
| TOXICOLOGY REVIEW | REPTED 30,495,2010 | |
| TOXICOLOGY REVIEW | MUREAV 750,132,2012 | |
| TOXICOLOGY REVIEW | MUREAV 750,1,2012 | |
| TOXICOLOGY REVIEW | MUREAV 760,1,2014 | |
| TOXICOLOGY REVIEW | JOETD7 181,66,2016 | |
| TOXICOLOGY REVIEW | JOETD7 181,118,2016 | |
| TOXICOLOGY REVIEW | RTOPDW 56,237,2010 | |
| TOXICOLOGY REVIEW | RTOPDW 58,395,2010 | |
| TOXICOLOGY REVIEW | SFDRA* 38,365,2016 | |
| TOXICOLOGY REVIEW | VETODR ,197,2018 | |
| TOXICOLOGY REVIEW | VETOX* ,357,2018 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES | Active registration | RBREV* -,351,1998 |
| Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV; | ||
| Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV | ||
| Occupational Exposure Limit-AUSTRALIA | time-weighted average 5 mg/m3, JUL2008 | |
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 5 mg/m3;KZW 10 mg/m3, inhal, 2007 | |
| Occupational Exposure Limit-BELGIUM | time-weighted average 5 mg/m3, MAR2002 | |
| Occupational Exposure Limit-DENMARK | time-weighted average 5 mg/m3, MAY2011 | |
| Occupational Exposure Limit-ICELAND | time-weighted average 5 mg/m3, NOV2011 | |
| Occupational Exposure Limit-KOREA | time-weighted average 5 mg/m3, 2006 | |
| Occupational Exposure Limit-NEW ZEALAND | time-weighted average 5 mg/m3, JAN2002 | |
| Occupational Exposure Limit-NORWAY | time-weighted average 5 gm/m3, JAN1999 | |
| Occupational Exposure Limit-PERU | time-weighted average 5 mg/m3, JUL2005 | |
| Occupational Exposure Limit-RUSSIA | short term exposure limit 0.5 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWITZERLAND | MAK-week 5 mg/m3, inhal, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 5 mg/m3, 2003 | |
| Occupational Exposure Limit-UNITED KINGDOM | time-weighted average 5 mg/m3, OCT2007 |
NIOSH Documentation and Surveillance
| Organization | Standard | Reference |
|---|---|---|
| National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO ACETYLSALICYLIC ACID-air | 10H time-weighted average 5 mg/m3 | NIOSH* DHHS #92-100,1992 |
| National Occupational Exposure Survey 1983 | Hazard Code X1189; Number of Industries 1; Total Number of Facilities 27; Number of Occupations 1; Total Number of Employees Exposed 191; Total Number of Female Employees Exposed 82 | |
| National Occupational Exposure Survey 1983 | Hazard Code 84517; Number of Industries 9; Total Number of Facilities 491; Number of Occupations 22; Total Number of Employees Exposed 10776; Total Number of Female Employees Exposed 6083 | |
| National Occupational Hazard Survey 1974 | Hazard Code 84517; Number of Industries 12; Total Number of Facilities 1746; Number of Occupations 16; Total Number of Employees Exposed 10452 |
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health